Radiation-induced cardiovascular disease: an overlooked role for DNA methylation?

Magy Sallam a,b, Mohammed Abderrafi Benotmane a, Sarah Baatout a,c, Pieter-Jan Guns b, and An Aerts a

Radiobiology Unit, Institute for Environment, Health and Safety, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium; Laboratory of Physiopharmacology, University of Antwerp, Wilrijk, Belgium; Department of Molecular Biotechnology, Ghent University, Ghent, Belgium

ABSTRACT
Radiotherapy in cancer treatment involves the use of ionizing radiation for cancer cell killing. Although radiotherapy has shown significant improvements on cancer recurrence and mortality, several radiation-induced adverse effects have been documented. Of these adverse effects, radiation-induced cardiovascular disease (CVD) is particularly prominent among patients receiving mediastinal radiotherapy, such as breast cancer and Hodgkin’s lymphoma patients. A number of mechanisms of radiation-induced CVD pathogenesis have been proposed such as endothelial inflammatory activation, premature endothelial senescence, increased ROS and mitochondrial dysfunction. However, current research seems to point to a so-far unexamined and potentially novel involvement of epigenetics in radiation-induced CVD pathogenesis. Firstly, epigenetic mechanisms have been implicated in CVD pathophysiology. In addition, several studies have shown that ionizing radiation can cause epigenetic modifications, especially DNA methylation alterations. As a result, this review aims to provide a summary of the current literature linking DNA methylation to radiation-induced CVD and thereby explore DNA methylation as a possible contributor to radiation-induced CVD pathogenesis.

CONTACT An Aerts an.aerts@sckcen.be Radiobiology Unit, Institute for Environment, Health and Safety, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Introduction

Mediastinal radiotherapy is an effective means employed in the treatment of breast cancer, lung cancer, oesophageal cancer, thymoma, and mediastinal lymphoma (Hodgkin’s lymphoma (HL), primary mediastinal B-cell lymphoma (PMBCl), and T-lymphoblastic lymphoma) [1–5]. However, radiotherapy comes with definite side effects such as radiation-induced cardiovascular disease (CVD). In breast cancer, significantly higher rate of major coronary events were observed in irradiated left-sided breast cancer patients over their right-sided breast cancer counterparts [6]. A reason for this difference could be the different mean heart doses after left sided and right sided breast cancer radiotherapy being 3.6 and 1.9 Gy respectively [6–8]. As for Hodgkin’s lymphoma, treatment most commonly employs, in addition to radiotherapy, cardiotoxic chemotherapeutic agents e.g. anthracycline. Consequently, lymphoma survivors have a 5.3–7.3 times increased risk of death from cardiac mortality when compared to the general population [9,10]. The mechanisms underlying radiation-induced CVD are not completely understood. Moreover, a possible contribution of epigenetics mechanisms has recently been proposed.

Previous research has linked altered DNA methylation to the development of many diseases including CVD [11,12]. Conversely, ionizing radiation has been shown to cause DNA methylation alterations both in vitro and in vivo [13–16]. Considering the common occurrence of DNA methylation alterations in CVD and after ionizing radiation exposure, we suggest a previously unaddressed involvement of DNA methylation in radiation-induced CVD.

Radiation in cancer therapy

Radiation therapy employs high doses of ionizing radiation to kill cancer cells and shrink tumours. Radiation exerts its signature lethal cellular effects either directly or indirectly. Indirect effects involve the hydrolysis of water molecules to produce free radicals which can damage cellular compounds, such as DNA [17]. Several factors affect the biological effectiveness of radiation, namely the linear energy transfer (LET), total dose, fractionation rate, and radiosensitivity of the targeted cells or tissues [18]. LET is the energy transferred to the tissue by ionizing radiation (IR) per unit tract length. Simply, more charged, slower moving alpha particles and neutrons have higher LET and subsequently deliver more cell damaging energy to tissues than lesser charged, faster moving X-rays and γ-rays [19].

Despite the beneficial outcomes of cancer radiotherapy, cardiac toxicity occurring due to incidental heart irradiation is an undesirable healthy tissue side effect [7]. Previously, the heart was considered insensitive to radiation doses less than 30 Gy in accordance to the law of Bergonie and Tribondeau [20,21]. According to which, the degree of radiosensitivity of a biological tissue is dependent on its growth rate and degree of differentiation. Consequently, the heart with its non-dividing tissue was dubbed rather non-radiosensitive [21]. However, it was shown that the incidence of excess major coronary events increased by 7.4% per 1 Gy increase in the mean heart dose delivered by breast cancer radiotherapy with no observed safe threshold of dose [6].

Radiation-induced CVD manifestations

Radiation-induced CVD can manifest in different ways: coronary heart disease, pericarditis, cardiomyopathy and valvular heart disease (Figure 1). Due to contemporary radiation-sparing techniques including prone position radiotherapy, image- and dose-guided radiotherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and deep inspirational breath hold (DIBH), the incidence of acute pericarditis and cardiomyopathy has been reduced [22–25]. Consequently, coronary heart disease accounts for most of the cardiac mortality attributable to radiotherapy with the first signs of cardiac toxicity typically appearing after 10–15 years of follow-up [26–28]. Risk factors for the development of radiation-induced CVD strongly overlap with conventional risk factors for CVD, such as diabetes, hypertension, obesity, smoking, chronic obstructive pulmonary disease (COPD) and hypercholesterolemia. Additionally, therapy-dependent factors such as the cumulative dose from radiotherapy,
chemotherapeutics (e.g. anthracyclins) and regular analgesic use represent additional risk factors [6,29].

**Radiation-induced coronary heart disease**

Radiation-induced coronary heart disease (CHD) - also referred to as myocardial ischaemia - is caused by atherosclerosis of medium and large vessels. The pathogenesis of atherosclerosis involves a complex interplay of lipid accumulation, local inflammation and smooth muscle cell proliferation resulting in the formation of atherosclerotic plaques. Stable atherosclerotic plaques may narrow the lumen and hamper blood flow. However, unstable plaques may rupture and cause total occlusion of blood flow through thrombosis, leading to myocardial infarction. The risk of developing radiation-induced CHD is proportional to dose. This risk also increases within the first 5 years after exposure to radiation and continues for at least 20 years. In addition, radiation-induced CHD occurs at $\leq 10\%$ of the tolerance dose of other cardiac tissues (e.g. 36–40 Gy mean heart dose for the pericardium and 40 Gy for the myocardium) [6,30,31].

Interestingly, similar radiation-induced atherosclerotic changes in the carotid artery were observed in Hodgkin's lymphoma patients who received neck radiotherapy [32,33]. This arterial thickening leads to an increased relative risk for transient ischaemic attack or ischaemic stroke ($\geq 2$ general population risk) [34,35].

**Radiation-induced pericarditis**

Radiation-induced pericarditis describes a state of acute or delayed onset pericardial inflammation. Acute radiation-induced pericarditis is an early side effect to high radiation doses. The tolerance dose of human pericardium is estimated to be a mean heart dose higher than 36 or 40 Gy or a dose of 50 Gy administered to more than 30% of the heart. Consequently, due to current radiation-sparing techniques, acute radiation-induced pericarditis is considered very rare. On the other hand, chronic radiation-induced pericarditis is one of the most common manifestations of radiation-induced CVD presenting months to years after radiotherapy. However, its risk has also decreased significantly due to the same radiation-sparing
techniques. Chronic radiation-induced pericarditis patients develop fibrous thickening of the pericardium even before manifestation of symptoms. This pericardial thickening might progress to chronic constrictive pericarditis which could then lead to intractable heart failure and will require pericardiectomy when it becomes symptomatic [30,36,37].

**Radiation-induced cardiomyopathy**

Radiation-induced cardiomyopathy most commonly occurs after previous valvular disease or myocardial infarction. The tolerance dose of the human myocardium is approximately 40 Gy. Consequently, pronounced radiation-induced cardiomyopathy occurs at higher doses. The most probable mechanism behind radiation-induced cardiomyopathy is radiation-induced microvasculature damage leading to capillary loss and myocardial hypoxia and cell death. Dead cells are replaced by fibrotic tissue leading to a reduction of myocardial elasticity and distensibility [30,31].

**Radiation-induced valvular disease**

Radiation-induced valvular disease risk is dose dependent with delayed onset (up to 20 years after radiotherapy). It leads to endocardial fibrosis which starts by thickening and calcification of the valvular endocardium [38,39].

**Mechanisms of radiation-induced CVD**

Radiation-induced CVD pathophysiology has been extensively described in literature [30,31,40–45]. Inflammatory changes as well as reactive oxygen species (ROS) production appear to be the main causes of the early radiation-induced cardiac tissue damage. On the other hand, persistence of this state of inflammation and oxidative stress results in the delayed radiation-induced tissue damage [44–47].

An early event in radiation-induced cardiac effects is NF-κB activation. NF-κB is a transcription factor implicated in the regulation of immune cell maturation, cell survival, and inflammation signalling pathways [48]. IR activates NF-κB through ROS and double stranded breaks (DSBs) as well as damage-associated molecular patterns (DAMPs) released from stressed or dying cells [42]. DAMP binding to endothelial cells also activates MAPK, and interferon regulatory factor 3 (IRF3) signalling [42,49]. This leads to the expression of various pro-inflammatory cytokines (e.g. Interleukins 1 & 6, interferon-γ (IFN-γ), and Tumour Necrosis Factor (TNF-α)), chemokines (e.g. Monocyte chemoattractant protein-1 or MCP-1), cell adhesion molecules (e.g. Vascular cell adhesion molecule 1 or VCAM-1 and E-Selectin) and matrix metalloproteinases. This ultimately initiates an acute inflammatory state with endothelial activation and inflammatory cell recruitment within minutes of IR exposure. The recruited inflammatory cells (mainly neutrophils) add to the inflammatory state and secrete pro-fibrotic transforming growth factor beta (TGF-β). TGF-β has been shown to initiate myocardial remodelling by inducing cardiac fibroblast differentiation into myofibroblast with increased collagen deposition and eventual fibrosis [50].

In addition to chronic inflammation, chronic oxidative stress is an important pathophysiologic mechanism of radiation-induced CVD. As previously mentioned, IR-induced ROS play a role in the activation of NF-κB. In addition, ROS upregulate several enzymes such as nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), lipoxigenases (LOXs), nitric oxide synthase (NOS), and cyclooxygenases (COXs). These enzymes contribute to the acute and chronic effects of oxidative stress by inducing production of inflammatory and pro-fibrotic cytokines, prostaglandin production, lipid peroxidation and inhibition of DNA repair [51].

Interestingly, recent studies showed an activation of nucleotide-binding domain and leucine-rich-repeat-containing family pyrin 3 (NLRP3) inflammasome after thoracic irradiation of C57BL/6 mice [52]. Irradiation of THP-1 monocytes led to a similar inflammasome activation resulting in increased expression of interleukin−1β (IL-1β) and IL-18 [52,53]. This is especially important as IL-1 secretion was suggested to participate in the development of radiation-induced CVD. This was further evidenced by amelioration of radiation induced sustained expression of inflammatory mediators in mice after
administration of IL-1β blocker directly after irradiation for 2 weeks [54,55].

This state of inflammation and oxidative stress is suggested to initiate a number of pathophysiologic dysfunctions. The first is cell death and premature endothelial senescence [56]. Aside from the direct apoptotic effects of radiation, irradiation of cardiac myocytes stimulates calcium release from the endoplasmic reticulum. This causes mitochondrial calcium overload, mitochondrial membrane swelling and release of apoptotic factors [44]. On the other hand, endothelial cell senescence occurs as a result of activation of Ataxia telangiectasia mutated (ATM)/p53/p21 and protein Kinase B/phosphatidylinositol 3-kinase/mechanistic target of rapamycin (Akt/PI3K/mTOR) pathways [42,56]. In addition, IL-6 induced by NF-κB activation has been previously identified as a critical controller of autocrine senescence [57–59]. Finally, accelerated telomere shortening induced by oxidative stress and mitochondrial dysfunction also contribute to accelerated endothelial senescence [57–60].

The second contributing pathophysiologic dysfunction is impaired endothelium-dependent relaxation of blood vessels. This is mediated mainly by endothelial nitric oxide synthase (eNOS) uncoupling and direct inactivation of NO by superoxide radicals leading to diminished vasodilation [61–64]. Senescent endothelial cells also contribute to decreased NO production due to their lowered eNOS activity [65]. In addition, decreased vasodilating prostacyclin and increased vasoconstrictive endothelin-1 and angiotensin-II levels contribute to chronic vasoconstriction [66,67]. The third contributing pathophysiologic dysfunction is mitochondrial dysfunction. Mitochondrial DNA is especially sensitive to radiation-induced damage due to its limited repair capacity, lack of protective histones, a high exon/intron ratio and its close proximity to the electron transport chain [42]. Furthermore, radiation-induced ROS can cause mutations in mitochondrial DNA as well as damage or alter the expression of proteins required for critical mitochondrial and cellular functions. The damaged mitochondria then generate more ROS which starts a vicious cycle of mitochondrial ROS generation [51,68].

The final contributing pathophysiologic dysfunction is initiation of a pro-coagulative and pro-thrombotic state. Endothelial cell damage with secreted pro-inflammatory cytokines induces the secretion of von Willebrand factor (vWF), platelet-activating factor and tissue factor while reducing thrombomodulin and prostacyclin production [42]. In addition, TGF-β released from irradiated endothelial cells induces fibrogenic activation of vascular smooth muscle cells leading to increased proliferation and migration [69]. This, along with decreased NO availability, leads to increased platelet aggregation and thrombus formation [42]. Recently, the European Society for Medical Oncology (ESMO) proposed aspirin as an antiplatelet as one of the cardioprotective treatments for patients receiving radiotherapy and having a high risk for CVD [70]. However, up to this moment, antiplatelet therapy has not proven to be beneficial in radiation-induced CVD [71–73]. Consequently, non-traditional therapies against CVD may need to be further investigated.

**DNA methylation: a possible overlooked mechanism in radiation-induced CVD?**

Epigenetic modifications involve different mechanisms, such as histone modifications, changes in DNA methylation and regulation of gene expression through micro-RNAs. Epigenetic modifications induce changes in gene expression that can occur without any changes in the primary DNA sequence. Moreover, epigenetic alterations could be transmitted to future progeny [74]. Alterations in DNA methylation are the most widely researched epigenetic changes and will be the focus of the current review.

**DNA methylation**

DNA methylation involves methylation of a cytosine base in a CpG dinucleotide to produce 5-methyl cytosine (5-mC). A process that is essential for silencing of transposable elements, genomic imprinting and X-chromosome inactivation [75]. 5-mC represents only ~1% of nucleic acids in the genome [76–78]. This low CpG frequency occurs due to cytosine deamination. Spontaneous cytosine deamination yields uracil. This uracil is then repaired by uracil glycosylase to cytosine. On the other hand,
deamination of 5-mC yields thymine which is not corrected by uracil glycosylase leading to a C/T transition. This C/T transition is the most frequent mutation observed in human diseases occurring 10–50 times more frequently than all other base transitions. Consequently, cytosine deamination is the main reason for the observed frequency of CpG dinucleotides being lower than the expected CpG frequency in the absence of deamination [79,80]. The biological significance of this C/T transition is especially apparent when considering arginine deamination. The codon for arginine aminoacid (CGA) can be changed upon oxidative deamination of 5-mC into a stop codon (TGA). The premature appearance of a stop codon leads to the production of truncated and usually inactive proteins [81].

The majority of CpG dinucleotides in the human genome are heavily methylated (~70%) with the rest being unmethylated and mainly part of so called CpG islands (CGIs). CGIs are defined as regions of DNA (>200 bps) that have a GC content of at least 50%, observed CpG frequency of at least 60% of the expected CpG frequency, lack methylation and consequently are not transcriptionally silenced [82]. The expected CpG frequency in the previous definition is the CpG frequency if no cytosine deamination occurs. This high content of CpGs allows for DNA methylation-mediated regulation of gene expression. About 70% of gene promoters are associated with these CGIs and around 50% of these CGIs contain transcription start sites [83]. Hyper- or hypomethylation of DNA has long been considered to inhibit or activate gene expression, respectively. However, the relationship between the DNA methylation state and gene expression is actually more complex as will be discussed later. Nonpromoter CGIs are CGIs that can be found in inter- and intragenic sequences. These CGIs represent either alternative transcription start sites of protein-coding genes or noncoding RNAs [84,85]. Intragenic or gene body CGIs that are present in actively expressed genes show increased DNA methylation. This can be due to gene body CGI’s ability to block transcription at intragenic promoters, affect intragenic repetitive element activity and alter mRNA splicing by destabilizing nucleosomes at intron-exon junctions [86]. In general, methylation at CGIs is relatively stable in normal healthy tissue with major methylation pattern alterations associated with various disease states including cancer [87].

Historically, DNA methylation can be classified into two main types: De novo methylation which happens mainly in the developing embryo and maintenance methylation which maintains the methylation patterns from the parent strand in the daughter strand during replication. Consequently, DNA methylation is an epigenetic pattern that is maintained in cellular progeny and is normally stable in non-dividing cells [88,89].

DNA methylation is carried out by the action of DNA methyltransferases or DNMTs. Initiation of DNA methylation in the growing embryo during implantation occurs under the effects of the de novo DNMTs (DNMT-3a and -3b) with the help of DNMT3 like (DNMT3l). Here, the de novo DNMTs transfer methyl groups from S-adenyl methionine (SAM) to cytosines of the unmethylated DNA strand. DNMT3l is a DNMT3 family member which is incapable of individual methyltransferase activity but increases the activity of DNMT-3a and -3b by up to threefold [89]. Following this initial methylation step, the maintenance DNMT (DNMT1) then replicates the methylation pattern in following cell divisions. There, DNMT1 methylates hemimethylated CpG dinucleotides at the replication fork where newly biosynthesized DNA strands are directly methylated (Figure 2) [78,89,90]. This ‘maintenance’ thereby allows inheritance of the methylation patterns of the parent cell. The addition of a methyl group to C5 of a cytosine leads to the production of a stable covalent bond that requires a high degree of energy to be broken. An observation that led to the mistaken belief of the irreversibility of DNA methylation [91,92].

While DNA methylation patterns are fairly stable over time, DNA can be demethylated as well. DNA demethylation can occur through passive and active mechanisms. Passive demethylation occurs by inhibition of -or reduction in- DNMT1 levels. This inhibition or reduction of DNMT1 allows newly incorporated cytosine to remain
a) De Novo Methylation

![De Novo Methylation Diagram](image)

b) Maintenance Methylation

![Maintenance Methylation Diagram](image)

Figure 2. The writers of DNA methylation. DNMTs transfer a methyl group from SAM to the 5th carbon of cytosine. (A) De novo methylation process in the developing embryo by the action of DNMT3a and DNMT3b. (B) Maintenance methylation process during DNA replication to maintain the methylation profile in the daughter cells by the action of DNMT1 present at the replication fork on hemimethylated DNA. DNMT: DNA methyltransferase, SAM: S – adenosyl methionine, SAH: S-adenosyl-L-homocysteine. Made with Biorender (biorender.com).

unmethylated thereby causing a replication-dependent dilution of 5-mC [78,93]. Active demethylation involves the modification of the methyl group of 5-mC by enzymatic action and subsequent restoration of the non-methylated cytosine by DNA repair. Active DNA demethylation is mainly mediated by the actions of ten eleven translocation (TET) enzyme [83].

**Does radiation impact DNA methylation and how?**

Radiation has been shown in previous studies to cause DNA methylation alterations [15,94–98]. However, the interplay between IR and DNA methylation is highly complex and may be tissue-dependent as well as model and strain-specific [99]. A summary of the literature [13–16,94–96,100–109] addressing the effect of radiation on DNA methylation is provided in Table 1 of Supplementary Materials.

Research addressing radiation-induced DNA methylation alterations was found to involve different radiation types, doses and sampling times. Subsequently, the task of arriving to a simple conclusion regarding the exact effects of IR on DNA methylation becomes extremely difficult. Some studies address the effects of IR exposure during spaceflight. Subsequently, those employ low doses of high LET protons and heavier high atomic number and energy (HZE) ions such as Fe radiation [94,96,107]. On the other hand, studies that address the effects of the medica application of radiation tend to use different types and doses of radiation in an attempt to mimic the doses regularly received by patients. In addition, even among those studies, different doses, dose intensities and study durations are employed. This is because of the varying aims of these studies which range from the investigation of radiation-induced carcinogenesis, radiation-induced genomic instability and bystander effects [13–15,95,101,102,109,110] to cellular responses to radiation and radiosensitivity [100,103,104,108]. In addition, some studies addressed the difference between the effects of IR on somatic and germinal tissues [16].

Another important and somewhat confounding aspect of the effects of IR on DNA methylation is the common use of in vivo animal models with rather short lifespan compared to humans. This is because the late effects of IR tend to develop in humans several years after the initial radiation. Consequently, investigating these late side effects in animal models requires taking into
### Table 1. Functional analysis of CVD differentially methylated genes in literature.

| PANTHER Pathways                              | Number of genes | raw P-value | False Discovery Rate (FDR) |
|-----------------------------------------------|-----------------|-------------|----------------------------|
| JAK/STAT signalling pathway                   | 3               | 0.0000      | 0.0010                     |
| Interferon-gamma signalling pathway           | 3               | 0.0001      | 0.0035                     |
| PI3 kinase pathway                            | 3               | 0.0003      | 0.0112                     |
| Interleukin signalling pathway                | 3               | 0.0012      | 0.0393                     |
| PDGF signalling pathway                       | 3               | 0.0048      | 0.1300                     |
| Angiogenesis                                  | 3               | 0.0076      | 0.1770                     |
| TGF-beta signalling pathway                   | 2               | 0.0222      | 0.4040                     |
| Inflammation mediated by chemokine and cytokine signalling pathway | 3 | 0.0214 | 0.4380 |
| Androgen/estrogen/progesterone biosynthesis   | 1               | 0.0295      | 0.4830                     |
| 5-Hydroxytryptamine degradation               | 1               | 0.0494      | 0.7360                     |
| Adrenaline and noradrenaline biosynthesis     | 1               | 0.0667      | 0.7810                     |
| Axon guidance mediated by Slit/Robo           | 1               | 0.0624      | 0.7870                     |
| CCKR signalling map                           | 2               | 0.0606      | 0.8280                     |
| Dopamine receptor mediated signalling pathway | 1               | 0.1250      | 1.0000                     |
| p53 pathway                                   | 1               | 0.1840      | 1.0000                     |
| Wnt signalling pathway                        | 2               | 0.1660      | 1.0000                     |
| VEGF signalling pathway                       | 1               | 0.1470      | 1.0000                     |
| p53 pathway feedback loops 2                 | 1               | 0.1110      | 1.0000                     |
| Ras Pathway                                  | 1               | 0.1590      | 1.0000                     |
| Oxidative stress response                     | 1               | 0.1210      | 1.0000                     |
| Gonadotropin-releasing hormone receptor pathway | 1  | 0.4170   | 1.0000                     |
| Endothelin signalling pathway                 | 1               | 0.1740      | 1.0000                     |
| EGF receptor signalling pathway               | 1               | 0.2710      | 1.0000                     |
| Cadherin signalling pathway                   | 1               | 0.3700      | 1.0000                     |
| Blood coagulation                            | 1               | 0.1030      | 1.0000                     |
| Apoptosis signalling pathway                  | 1               | 0.2350      | 1.0000                     |
| Alzheimer disease-presenilin pathway          | 1               | 0.2500      | 1.0000                     |

consideration the equivalent age of the animals [111]. This is indeed difficult as there are wide variations in the developmental durations and phases of these animals versus humans. Consequently, special considerations to the exact developmental stage of the used animal model are necessary to correlate the results to human stage [112].

Despite these difficulties, these studies share trends in DNA methylation alterations in response to IR analysed on both a global and a gene-specific scale. Global DNA methylation offers a representation of the total 5-mC content in the genome, but lacks gene-specific information. On the other hand, gene-specific methylation focuses on the methylation alterations of specific genes. In Figure 3, we attempt to summarize the studies addressing the effect of radiation on DNA methylation from a global DNA methylation perspective. In Figure 3, we observe a general trend of radiation-induced global hypomethylation which persists for several months in a number of studies employing animal models. This suggests a link between DNA methylation alterations and IR-induced late effects observed years after radiotherapy [14,94,96,110]. Global hypomethylation is mainly evaluated by the methylation of DNA repetitive elements (REs) which account for about 50% of the human genome. Of which, Alu element (Alu) and long interspersed element-1 (LINE-1) are the most abundant human RE sequences. Hypomethylation of these REs will therefore lead to their reactivation, retrotransposition and resultant genomic instability [113]. On the other hand, attempting a similar overview for gene-specific methylation is more difficult. Different studies reported different sets of methylated genes with no clear patterns. Of note, IR was reported to elicit both hyper- and hypomethylation of individual genes. However, overall radiation-induced gene-specific hypermethylation occurred at a higher frequency than gene-specific hypomethylation.

Within these literature studies, a number of possible mechanisms have been put forward (Figure 4). The first mechanism involves ROS produced by radiation-induced water hydrolysis. These ROS are able to alter DNA methylation patterns through several ways [114]. ROS may act directly on the DNA by oxidizing the guanine base in CGIs forming 8-oxo-20-deoxyguanosine (8-OHdG), which can be repaired by its removal by 8-oxoguanine DNA glycosylase (OGG1) followed by base excision repair (BER). If not repaired, 8-OHdG can prevent the methylation of the adjacent cytosine leading to subsequent hypomethylation. Alternatively, ROS may directly convert 5-mC to 5-hydroxyl mC by interaction of DNA with hydroxyl radicals. ROS may affect DNA methylation indirectly by altering the activity of methylation related enzymes [114]. However, ROS effects on DNMTs seem to be bidirectional. ROS can lead to hypermethylation by upregulating DNMTs or increasing their recruitment by H2O2. ROS can also lead to hypomethylation by reducing the availability of SAM.
which is an essential cofactor for DNMT activity. Finally, other studies have shown that ROS can lead to DNA hypermethylation due to their nucleophilic action on the 5 position of cytosine molecule leading to its deprotonation and accelerating its reaction with SAM [115,116]. In summary, ROS can lead to hypomethylation by 8-OHdG formation, 5-mC hydroxylation or reducing SAM availability. On the other hand, ROS can also lead to hypermethylation by DNMT upregulation or increased recruitment as well as 5-mC deprotonation. Despite the counter intuitiveness of ROS having opposing effects on DNA methylation, this ‘dual’ effect may contribute to the observed similar opposing effects of radiation on DNA methylation.

Secondly, radiation can also cause DNA hypermethylation by activation of NF-κB [117--117--120]. NF-κB activation leads to alterations in DNA methylation through two different mechanisms. Firstly, the RelA/p65 subunit of NF-κB can directly recruit DNMT-1 to chromatin [121]. Secondly, NF-κB regulates DNA methylation indirectly by the production of Interleukin-6 (IL-6), which has been shown to also regulate DNMT1 expression leading to increased DNMT1 activity [122--124]. This increased availability/activity of DNMT1 subsequently leads to hypermethylation.

**DNA methylation and CVD; possible disease collaborator?**

A number of studies have linked DNA methylation alterations to CVD development [125--125--157]. The focus of these studies is mostly atherosclerosis as it is the underlying cause of most CVDs [158--164]. In most cases, global DNA hypomethylation has been observed in atherosclerosis [165--170]. This state of hypomethylation was detectable in atherosclerosis prone murine aorta even before the development of atherosclerosis [171]. In addition, gene specific hypermethylation has also been

---

*Figure 3. Overview of the shared outcomes of the different studies involving radiation-induced global methylation. Made with createply (creately.com) and Microsoft Powerpoint.*
observed in atherosclerosis [147,151,156]. Interestingly, focal gene-specific hypermethylation offers higher biological relevance than that of global hypomethylation [162].

We examined the literature concerning differentially methylated genes in CVD (summarized in Table 2 of Supplementary Materials). In most cases, identified differentially methylated genes are associated with key elements in CVD pathogenesis, such as lipid metabolism, inflammation, oxidative stress, atherosclerosis and endothelial cell dysfunction. This consequently points to a contribution of DNA methylation to CVD pathophysiology. However, care should be taken when translating DNA methylation data from these studies to clinically relevant biomarkers. This is in part due to the fact that the effect of DNA methylation on gene expression is of a complex nature. Several studies have pointed out that the state of CpG methylation does not always predict the state of gene expression. Indeed, examination of the DNA methylation of primary human fibroblasts showed that CpG methylation alterations did not always translate to changes in gene expression [172,173].

Furthermore, it was found that better correlation with gene expression was encountered with certain genomic positions (first intron) or associated with chromatin states, particularly those that are representative of active chromatin and transcribed regions [172,174,175]. Another confounder is that many studies investigating differential methylation in CVD are based on a limited, rather low, number of samples which casts doubt on the capacity to extrapolate the results. Therefore, care must be taken when interpreting the results originating from low sample size or those not backed up with gene expression analyses.

The association between altered DNA methylation and CVD is further proven in experimental models of atherosclerosis. Dunn et al. have shown DNMT inhibitor 5-Aza-2’-deoxycytidine (also known as decitabine) to be effective atheroma preventive measures in a ApoE−/− mouse model of atherosclerosis [176]. In addition, decitabine was shown to decrease atherosclerosis development in LDLr−/− mice through decreased macrophage inflammation and suppressed macrophage endoplasmic reticulum stress [177]. This could be
explained by decreased methylation and subsequent increased expression of liver X receptor α (LXRα) and peroxisome proliferator-activated receptor γ1 (PPARγ). LXRα and PPARγ are atheroprotective as they regulate lipid metabolism and macrophage inflammation [178–180]. The interested reader is referred to a number of reviews regarding the use of DNA methylation inhibitors as candidates drugs for treating atherosclerosis [181–183].

**Functional analysis of differentially methylated genes in CVD**

In an attempt to validate the involvement of DNA methylation in CVD pathogenesis, we performed a functional analysis of genes reported in literature to be differentially methylated in CVD (Table 1). This was done by investigating these genes in the pathway analysis functionality of PANTHER (protein analysis through evolutionary relationships) classification system [184,185]. Our PANTHER analysis of differently methylated genes in Table 1 reveals that these genes were connected to a number of pathophysiological mechanisms of CVD, such as inflammation, oxidative stress and endothelial activation. In addition, four pathways showed statistically significant pathway involvement, namely Janus kinase/signal transducers and activators of transcription (JAK/STAT) signalling pathway, interferon-gamma (INF-γ) signalling pathway, phosphoinositide 3 kinase (PI3K) pathway and interleukin signalling pathway. This should come as no surprise as these pathways are associated with cardiac myocyte response to injury and stress as well as cardiovascular inflammation [186–194]. Activation of JAK/STAT signalling contributes to atherosclerosis development by aiding immune cell recruitment and vascular smooth muscle proliferation, hypertrophy, and migration [195]. In addition, STAT1 synergizes with NF-κB in its inflammatory signalling [196]. Conversely, IFN-γ promotes endothelial cell adhesion, immune cell recruitment with a conflicting effect on foam cell formation [197–199]. Also, PI3K catalyzes second messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP3) production. In the heart, four isoforms (PI3Ka, PI3Kβ, PI3Kδ, and PI3Kγ) are differentially expressed in different cell subsets (cardiomycocytes, fibroblasts, endothelial cells and vascular smooth muscle cells). Subsequently, they are associated with varying effects on myocardial contractility, physiological growth and pathobiological remodelling as well as smooth muscle cell and immune cell migration [200–202]. In addition, PI3Ks function as scaffolding proteins in cardiac excitation-contraction coupling and autophagy [201]. Finally, interleukins are a family of cytokines strongly associated with chronic inflammation and atherogenesis. Some interleukins can have proatherogenic effects while fewer interleukins can have atheroprotective effects [197,203–208]. These DNA methylation alterations in pathways associated with atherogenesis suggest a usefulness for DNA methylation based CVD biomarkers. First, Istas et al. found that differentially methylated regions in BRCA1 and CRISP2 genes were reproducibly differentially methylated in independent atherosclerotic human aorta tissue and human carotid plaque samples [156]. In addition, these methylation changes at BRCA1 and CRISP2 genes were consistently associated with subclinical atherosclerosis in an independent sample cohort of middle-aged men. This study provides a concrete example of how genespecific methylation could be used to monitor the development of atherosclerosis, even before the condition is clinically diagnosable [156]. Second, p16INK4a was found to be differentially methylated by IR while also influencing epicardial adipose tissue development and subsequent CVD risk [209]. This intersection of gene-specific methylation alterations observed after radiation and associated with CVD could offer an untapped source of functional biomarkers.

**Conclusions and future directions**

DNA methylation is an epigenetic mechanism that has been shown to be implicated in the pathogenesis of many diseases. In healthy individuals, the CpG islands in promoter regions are normally non-methylated thereby allowing their associated genes to be transcriptionally active. For the rest of the genome, CpG dinucleotides are normally methylated. Predictably, alterations in DNA methylation lead to changes in gene expression.
Ionizing radiation has been shown in several studies to cause DNA methylation alterations; most commonly global DNA hypomethylation and gene-specific hypermethylation. However, studies investigating radiation-induced DNA methylation alterations vary in radiation LET and dose, type of investigated model as well as the sampling timeline. These variations make it difficult to answer important questions regarding the possible differences in effect on DNA methylation between high and low LET radiation, as well as if there is a dose threshold that needs to be reached to cause DNA methylation alterations. However, the persistence of radiation-induced DNA methylation alterations after IR exposure suggests the involvement of these DNA methylation alterations in radiation-induced late effects.

On the other hand, several studies reported global hypomethylation in CVD and specifically in atherosclerosis. In addition, hyper- and -less commonly- hypo-methylation of specific genes has also been reported in CVD. Through a gene ontology analysis, we found that the genes that have been reported to be differentially methylated in CVD are associated with pathways related to CVD pathogenesis, such as endothelial activation, oxidative stress and inflammation.

One of the most common adverse effects of mediastinal radiotherapy is radiation-induced CVD, which has the same presentation as atherosclerosis. Radiation-induced DNA damage, oxidative stress and inflammation are considered as major molecular drivers of radiation-induced CVD. Various therapeutic techniques have been employed to reduce the accidental irradiation of the heart during radiotherapy such as prone position radiotherapy, image- and dose-guided radiotherapy, IMRT, SBRT and DIBH. However, despite substantially reducing the dose of the accidental irradiation, radiation-induced cardiac events continue to occur. Furthermore, research is exploring protective agents which interfere with one or more of the identified pathophysiological mechanisms of radiation-induced CVD mainly through reducing chronic inflammation and oxidative stress [44,210,211]. In addition, non-traditional therapies against CVD are worth exploring.

The late-onset aspect of radiation-induced CVD constitutes a diagnostic challenge to timely initiation of cardioprotective therapy. Interestingly, radiation-induced DNA methylation alterations are notable immediately after irradiation and often persist long after it. Therefore, DNA methylation alterations in radiation-induced CVD could serve as novel, early biomarkers e.g. p16INK4a.

To the extent of our knowledge, no experimental research has directly investigated the correlation between radiation-induced DNA methylation alterations and resultant CVD. Previous research suggests the possibility of performing targeted DNA methylation [212] and demethylation [213,214]. This would allow studying the effect of prevention/induction of radiation-induced methylation alterations of specific genes. Subsequent effects on gene expression and induction of CVD pathophysiology could then serve as a means to test our theory. It is therefore our recommendation that future studies direct their attention to examining targeted radiation-induced DNA methylation alterations and their involvement in CVD pathogenesis. [194,215–271]

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This project (MEDIRAD) has received funding from the Euratom research and training programme 2014-2018 under grant agreement No 755523.

ORCID

Magy Sallam  http://orcid.org/0000-0002-3040-8993
Pieter-Jan Guns  http://orcid.org/0000-0002-8640-6620

References

[1] Ratosa I, Ivanetic Pantar M. Cardiotoxicity of mediastinal radiotherapy. Rep Pract Oncol Radiother. 2019;24:629–643.
[2] Hoppe BS, Bates JE, Mendenhall NP, et al. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pract Radiat Oncol. 2020;10(3):e147–54.
[3] Van Nimwegen FA, Tsentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257–2265.
[4] Pohjola-Sintonen S, Töterman KJ, Salmo M, et al. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin’s disease. Cancer. 1987;60(1):31–37.

[5] Hahn E, Jiang H, Ng A, et al. Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(3):1116–1123.

[6] Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14;368(11):987–998.

[7] Drost L, Yee C, Lam H, et al. A systematic review of heart dose in breast radiotherapy. Clin Breast Cancer. 2018 Oct 1;18(5):e819–24.

[8] Bogaard VAB, van Den, Ta BDP, Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017 Apr 10;35(11):1171.

[9] Yu AF, Jones LW. Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training. Future Cardiol. 2015;11(4):441–452.

[10] Boyne DJ, Mickle AT, Brenner DR, et al. Long-term risk of cardiovascular mortality in lymphoma survivors: a systematic review and meta-analysis. Cancer Med. 2018;7(9):4801–4813.

[11] Muka T, Koromani F, Portilla E, et al. The role of epigenetic modifications in cardiovascular disease: a systematic review. Int J Cardiol. 2016 Jun 1;212:174–183.

[12] Zhong J, Agha G, Baccarelli AA. The role of DNA methylation in cardiovascular risk and disease: methodological aspects, study design, and data analysis for epidemiological studies. Circ Res. 2016 Jan 8;118(1):119–131.

[13] Loree J, Koturbash I, Kutanzi K, et al. Radiation-induced molecular changes in rat mammary tissue: possible implications for radiation-induced carcinogenesis. Int J Radiat Biol. 2006 Jan 3;82(11):805–815.

[14] Luzhna L, Il’nyts’ky V, Kovalchuk O. Mobilization of LINE-1 in irradiated mammary gland tissue may potentially contribute to low dose radiation-induced genomic instability. Genes Cancer. 2015;6(1–2):71–81.

[15] Pogribny I, Koturbash I, Tryndyak V, et al. Fractionated low-dose radiation exposure leads to accumulation of DNA damage and profound alterations in DNA and histone methylation in the murine thymus. Mol Cancer Res. 2005 Oct 1;3(10):553–561.

[16] Jangiam W, Udomtankaunkhai C, Reungpatthanaphong P, et al. Late effects of low-dose radiation on the bone marrow, lung, and testis collected from the same exposed BALB/cj Mice. Dose-Response. 2018 Oct 19;16(4):155932581881503.

[17] Desouky O, Ding N, Zhou G. Targeted and non-targeted effects of ionizing radiation. J Radiat Res Appl Sci. 2015 Apr 1;8(2):247–254.

[18] Baskar R, Dai J, Wenlorn N, et al. Biological response of cancer cells to radiation treatment. Front Mol Biosci. 2014;1:24.

[19] Balaji K, Subramanian B, Yadav P, et al. Radiation therapy for breast cancer: literature review. Med Dosim. 2016;41(3):253–257.

[20] Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):656–665.

[21] Hayes AW. Principles and methods of toxicology. 5th ed. CRC Press; 2007.

[22] Citrin DE, Mitchell JB. Mechanisms of normal tissue injury from irradiation. Semin Radiat Oncol. 2017;27(4):316–324.

[23] De Ruyscher D, Niedermann G, Burnet NG, et al. Radiotherapy toxicity. Nat Rev Dis Prim. 2019 Dec 21;5(1):13.

[24] Spetz J, Mosleh J, Sarosiek K. Radiation-induced cardiovascular toxicity: mechanisms, prevention, and treatment. Curr Treat Options Cardio Med. 2018 Apr 20;20(4):31.

[25] Cui S, Li W, Lv X, et al. Folic acid supplementation delays atherosclerotic lesion development by modulating MCP1 and VEGF DNA methylation levels in vivo and in vitro. Int J Mol Sci. 2017 May 5;18(5):990.

[26] Cuomo JR, Javaheri SP, Sharma GK, et al. How to prevent and manage radiation-induced coronary artery disease. Heart. 2018;104(20):1647–1653.

[27] Armanious MA, Mohammadi H, Khodor S, et al. Cardiovascular effects of radiation therapy. Curr Prob Cancer. 2018;42:433–442.

[28] Tapio S. Pathology and biology of radiation-induced cardiac disease. J Radiat Res. 2016 Sep 1;57(5):439–448.

[29] Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European association of cardiovascular imaging and the American society of echocardiography. J Am Soc Echocardiogr. 2013;26(9):1013–1032.

[30] Cuomo JR, Sharma GK, Conger PD, et al. Novel concepts in radiation-induced cardiovascular disease. World J Cardiol. 2016 Sep 26;8(9):504–519.

[31] Taunk NK, Haffty BG, Kostis JB, et al. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015;5:39.

[32] Dorrestein LD, Stewart FA, Boogerd W. Stroke as a late treatment effect of Hodgkin’s disease. J Clin
72 M. SALLAM ET AL.

Oncol. 2006;24(9):1480. DOI:10.1200/JCO.2005.04.8538.

[33] Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin’s disease: a report from the childhood cancer survivor study. J Clin Oncol. 2005 Sep 20;23(27):6508–6515.

[34] Plummer C, Henderson RD, O’Sullivan JD, et al. Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. Stroke. 2011;42(9):2410–2418.

[35] Dorresteijn LDA, Kappelle AC, Scholz NMJ, et al. Increased carotid wall thickening after radiotherapy on the neck. Eur J Cancer. 2005 May 1;41(7):1026–1030.

[36] Yusuf SW, Venkatesulu BP, Mahadevan LS, et al. Radiation-induced cardiovascular disease: a clinical perspective. Front Cardiovasc Med. 2017;26:4.

[37] Baselet B, Rombouts C, Benotmane AM, et al. Cardiovascular diseases related to ionizing radiation: the risk of low-dose exposure (Review). Int J Mol Med. 2016 Dec 1;38(6):1623–1641.

[38] Heidenreich PA, Kapoor JR. Radiation induced heart disease. Heart. 2008 Nov 25;95(3):252–258.

[39] Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart. 2016 Feb 15;102(4):269–276.

[40] Halle M, Hall P, Tornvall P. Cardiovascular disease associated with radiotherapy: activation of nuclear factor kappa-B. J Intern Med. 2011 May;269(5):469–477.

[41] Sylvester CB, Abe J, Patel ZS, et al. Radiation-induced cardiovascular disease: mechanisms and importance of linear energy transfer. Front Cardiovasc Med. 2018;5:5.

[42] Baselet B, Sonveaux P, Baoutou S, et al. Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci. 2019;76:699–728.

[43] Li M, You L, Xue J, et al. Ionizing radiation-induced cellular senescence in normal, non-transformed cells and the involved DNA damage response: a mini review. Front Pharmacol. 2018;9:522.

[44] Wang H, Wei J, Zheng Q, et al. Radiation-induced heart disease: a review of classification, mechanism and prevention. Int J Biol Sci. 2019;15 (10):2128–2138.

[45] Halle M, Gabrielsen A, Paulsson-Berne G, et al. Sustained inflammation due to nuclear factor-kappaB activation in irradiated human arteries. J Am Coll Cardiol. 2010 Mar 23;55(12):1227–1236.

[46] Zhao W, Robbins M. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem. 2008 Dec 30;16(2):130–143.

[47] Lee Chuy K, Nahhas O, Dominic P, et al. Cardiovascular complications associated with mediastinal radiation. Curr Treat Options Cardiovasc Med. 2019;21(7):1–20.

[48] Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ Res. 2011;108(9):1122–1132.

[49] LandWG. The role of damage-associated molecular patterns (DAMPs) in human diseases part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. Sultan Qaboos Univ Med J. 2015;15(2):e157–70.

[50] Parichatikanond W, Luangmonkong T, Mangmool S, et al. Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on tgf-β Signaling. Front Cardiovasc Med. 2020;7:34.

[51] Wei J, Wang B, Wang H, et al. Radiation-induced normal tissue damage: oxidative stress and epigenetic mechanisms. Oxid Med Cell Longev. 2019;2019(4):1–11.

[52] Li X, Gong Y, Li D, et al. Low-dose radiation therapy promotes radiation pneumonitis by activating NLRP3 inflammasome. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):804–814.

[53] Huang S, Che J, Chu Q, et al. The role of NLRP3 inflammasome in radiation-induced cardiovascular injury. Front Cell Dev Biol. 2020;8:140.

[54] Mezzaroma E, Mikkelsen RB, Toldo S, et al. Role of interleukin-1 in radiation-induced cardiomyopathy. Mol Med. 2015;21(1):210–218.

[55] Christersdottir T, Pirault J, Gistera A, et al. Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade. Eur Heart J. 2019 Aug 7;40 (30):2495–2503.

[56] Wang Y, Boerma M, Zhou D. Ionizing radiation-induced endothelial cell senescence and cardiovascular diseases. Radiat Res. 2016 Aug;186(2):153–161.

[57] Liu Y, Bloom SI, Donato AJ. The role of senescence, telomere dysfunction and shelterin in vascular aging. Microcirculation. 2019;26(2):e12487. DOI:10.1111/mic.12487. Wiley Blackwell

[58] Ayouaz A, Raynaud C, Heride C, et al. Telomeres: hallmarks of radiosensitivity. Biochimie. 2008;90 (1):60–72. DOI:10.1016/j.biochi.2007.09.011.

[59] Lustig A, Shertov I, Geyer S, et al. Long term effects of radiation exposure on telomere lengths of leukocytes and its associated biomarkers among atomic-bomb survivors. Oncotarget. 2016;7(26):38989–38998.

[60] Minamino T, Komuro I. Role of telomere in endothelial dysfunction in atherosclerosis. Curr Opin Lipidol. 2002;13(5):537–543.

[61] Sugihara T, Hattori Y, Yamamoto Y, et al. Preferential impairment of nitric oxide-mediated endothelium-dependent relaxation in human cervical arteries after irradiation. Circulation. 1999 Aug 10;100(6):635–641.

[62] Beckman JA, Thakore A, Kalinowski BH, et al. Radiation therapy impairs endothelium-dependent vasodilation in humans. J Am Coll Cardiol. 2001 Mar 1;37(3):761–765.

[63] Pathak R, Cheema AK, Boca SM, et al. Modulation of radiation response by the tetrahydrobiopterin pathway. Antioxidants. 2015;4(1):68–81.

[64] Hong CW, Kim YM, Pyo H, et al. Involvement of inducible nitric oxide synthase in radiation-Induced
vascular endothelial damage. J Radiat Res. 2013 Nov;54(6):1036–1042.

[65] Donato AJ, Morgan RG, Walker AE, et al. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol. 2015;89:122–135.

[66] Estrada-Garcia L, Carrera-Rotllan J, Puig-Parellada P. Effects of oxidative stress and antioxidant treatments on eicosanoid synthesis and lipid peroxidation in long term human umbilical vein endothelial cells culture. Prostaglandins Other Lipid Mediat. 2002;67 (1):13–25.

[67] Fardid R, Najafi M, Salajegheh A, et al. Radiation-induced non-targeted effect in vivo: evaluation of cyclooxygenase-2 and endothelin-1 gene expression in rat heart tissues. J Cancer Res Ther. 2017 Jan 1;13(1):51–55.

[68] Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett. 2012;327(1–2):48–60.

[69] Milliat F, François A, Isoir M, et al. Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages. Am J Pathol. 2006;169(4):1484–1495.

[70] Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31 (2):171–190.

[71] RON WAKSMAN, PAKALA R, ROY P, et al. Effect of clopidogrel on neointimal formation and inflammation in balloon-denuded and radiated hypercholesterolemic Rabbit iliac arteries. J Interv Cardiol. 2008;21 (2):122–128.

[72] Hoving S, Heeneman S, Gijbels MJJ, et al. NO-donating aspirin and aspirin partially inhibit age-related atherosclerosis but not radiation-induced atherosclerosis in ApoE null mice. PLoS One. 2010;5 (9):1–10.

[73] Hoving S, Heeneman S, Gijbels MJJ, et al. Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. Radiother Oncol. 2011;101(1):100–108. DOI:10.1016/j.radonc.2011.09.019.

[74] Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010 Oct 13;28 (10):1057–1068.

[75] Ren W, Gao L, Song J. Structural basis of DNMT1 and DNMT3A-mediated DNA methylation. Genes (Basel). 2018 Dec 11;9(12):620.

[76] Lövkvist C, Dodd IB, Sneppen K, et al. DNA methylation in human epigenomes depends on local topology of CpG sites. Nucleic Acids Res. 2016 Jun 20;44 (11):5123–5132.

[77] Walsh CP, Xu GL. Cytosine methylation and DNA repair. In: Current topics in microbiology and immunology. Springer Verlag; 2006. p. 283–315.

[78] Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013 Jan;38(1):23–38.

[79] Fryxell KJ, Moon W-J. CpG mutation rates in the human genome are highly dependent on local GC content. Mol Biol Evol. 2005 Mar 1;22 (3):650–658.

[80] Carlberg C, Molnár F. DNA methylation. In: Human epigenomics. Singapore: Springer Singapore; 2018. p. 57–73.

[81] Romanov GA, Sukhoverov VS. Arginine CGA codons as a source of nonsense mutations: a possible role in multivariant gene expression, control of mRNA quality, and aging. Mol Genet Genomics. 2017 Oct 1;292 (5):1013–1026.

[82] Strichman-Almashanu LZ, Lee RS, Onyango PO, et al. A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. Genome Res. 2002 Mar 20;12 (4):543–554.

[83] Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell. 2014;156(1–2):45–68.

[84] Sarda S, Das A, Vinson C, et al. Distal CpG islands can serve as alternative promoters to transcribe genes with silenced proximal promoters. Genome Res. 2017 Apr;27(4):553–566.

[85] Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011 May 15;25 (10):1010–1022.

[86] Yang X, Han H, De Carvalho DD, et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014 Oct.;26(4):577–590.

[87] Luo C, Hajkova P, Ecker JR. Dynamic DNA methylation: in the right place at the right time. Science. 2018;361(6409):1336–1340.

[88] Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002 Jan 1;16(1):6–21.

[89] Feng J, Fan G. Chapter- 4 the role of DNA methylation in the central nervous system and neuropsychiatric disorders. Nov Approaches to Stud Basal Ganglia Relat Neuropsychiatr Disord. 2009;89:67–84. http://www.sciencedirect.com/science/article/pii/S0074774209890041

[90] Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006 Feb 1;31(2):89–97.

[91] Ambrosi C, Manzo M, Baubec T. Dynamics and context-dependent roles of DNA methylation. J Mol Biol. 2017;429(10):1459–1475.

[92] Unoki M. Recent insights into the mechanisms of De novo and maintenance of DNA methylation in
mammals. In: DNA methylation mechanism. IntechOpen; 2019.

[93] Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. Cell. 2011 Sep 16;146(6):866–872.

[94] Miouse IR, Shao L, Chang J, et al. Exposure to low-dose 56 Fe-ion radiation induces long-term epigenetic alterations in mouse bone marrow hematopoietic progenitor and stem cells. Radiat Res. 2014;182(1):92–101.

[95] Miouse IR, Chang J, Shao L, et al. Inter-strain differences in LINE-1 DNA methylation in the mouse hematopoietic system in response to exposure to ionizing radiation. Int J Mol Sci. 2017 Jul 4;18(7):1430.

[96] Kennedy EM, Powell DR, Li Z, et al. Galactic cosmic radiation induces persistent epigenome alterations relevant to human lung cancer. Sci Rep. 2018 Dec 1;8(1):1–14.

[97] Koturbash I, Pogribny I, Kovalchuk O. Stable loss of global DNA methylation in the radiation-target tissue — A possible mechanism contributing to radiation carcinogenesis?. Biochem Biophys Res Commun. 2005 Nov 18;337(2):526–532.

[98] Tawa R, Kimura Y KOMURAJ-I, MIYAMURA Y, et al. Effects of X-ray irradiation on genomic DNA methylation levels in mouse tissues. J Radiat Res. 1998 Dec;39(4):271–278.

[99] Miouse IR, Kutanzi KR, Koturbash I. Effects of ionizing radiation on DNA methylation: from experimental biology to clinical applications. Int J Radiat Biol. 2017 May;93(5):457–469.

[100] Chaudhry MA, Omaruddin RA. Differential DNA methylation alterations in radiation-sensitive and -resistant cells. DNA Cell Biol. 2012 Jun 1;31(6):908–916.

[101] Goetz W, Morgan MNM, Baulch JE. The effect of radiation quality on genomic DNA methylation profiles in irradiated human cell lines. Radiat Res. 2011 May;175(5):575–587.

[102] Kalinich JF, Catravas GN, Snyder SL. The effect of γ radiation on DNA methylation. Radiat Res. 1989 Feb;117(2):185.

[103] Kuhmann C, Weichenhan D, Rehli M, et al. DNA methylation changes in cells regrowing after fractioned ionizing radiation. Radiother Oncol. 2011 Oct 1;101(1):116–121.

[104] Wang J, Zhang Y, Xu K, et al. Genome-wide screen of DNA methylation changes induced by low dose X-ray radiation in mice. PLoS One. 2014;9(3):e90804.

[105] Koturbash I, Boyko A, Rodriguez-Juarez R, et al. Role of epigenetic effectors in maintenance of the long-term persistent bystander effect in spleen in vivo. Carcinogenesis. 2007 Aug 1;28(8):1831–1838.

[106] Kumar A, Rai PS, Upadhya R, et al. γ-radiation induces cellular sensitivity and aberrant methylation in human tumor cell lines. Int J Radiat Biol. 2011 Nov 7;87(11):1086–1096.

[107] Acharya MM, Badhour AAD, Kawashita T, et al. Epigenetic determinants of space radiation-induced cognitive dysfunction. Sci Rep. 2017 Feb 21;7(1):1–15.

[108] Antwi DA, Gabbara KM, Lancaster WD, et al. Radiation-induced epigenetic DNA methylation modification of radiation-response pathways. Epigenetics. 2013 Aug 27;8(8):839–848.

[109] Aypar U, Morgan WF, Baulch JE. Radiation-induced epigenetic alterations after low and high LET irradiations. Mutat Res Mol Mech Mutagen. 2011 Feb 10;707(1-2):24–33.

[110] Koturbash I, Miouse IR, Sridharan V, et al. Radiation-induced changes in DNA methylation of repetitive elements in the mouse heart. Mutat Res. 2016;787:43–53.

[111] Sengupta P. The laboratory rat: relating its age with human’s. Int J Prev Med. 2013;4(6):624–630.

[112] Dutta S, Sengupta P. Men and mice: relating their ages. Life Sci. 2016;152:244–248.

[113] Zheng Y, Joyce BT, Liu L, et al. Prediction of genome-wide DNA methylation in repetitive elements. Nucleic Acids Res. 2017 Sep 1;45(15):8697–8711.

[114] Kietzmann T, Petry A, Shvetsova A, et al. The epigenetic landscape related to reactive oxygen species formation in the cardiovascular system. Br J Pharmacol. 2017;174(12):1533–1554.

[115] Yara S, Laviole J-C LE. Oxidative stress and DNA methylation regulation in the metabolic syndrome. Epigenomics. 2015 Apr;7(2):283–300.

[116] Wu Q, Ni X. ROS-mediated DNA methylation pattern alterations in carcinogenesis. Curr Drug Targets. 2015;16(1):13–19.

[117] Lee S-J, Dimtchev A, Lavin MF, et al. A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-κB. Oncogene. 1998 Oct 9;17(14):1821–1826.

[118] Janssens S, Tschopp J. Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ. 2006 May 13;13(5):773–784.

[119] Hei TK, Zhou H, Chai Y, et al. Radiation induced non-targeted response: mechanism and potential clinical implications. Curr Mol Pharmacol. 2011 Jun;4(2):96–105.

[120] Di Maggio F, Minafra L, Forte G, et al. Portrait of inflammatory response to ionizing radiation treatment. J Inflamm. 2015 Feb 18;12(1):14.

[121] Liu Y, Mayo MW, Nagji AS, et al. Phosphorylation of RelA/p65 promotes DNMT1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1. Oncogene. 2012 Mar 18;31(9):1143–1154.

[122] Li Y, Deuring J, Peppelenbosch MP, et al. 6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis. 2012 Oct 1;33(10):1889–1896.
[123] Brasier AR. The nuclear factor- B-interleukin-6 signaling pathway mediating vascular inflammation. Cardiovasc Res. 2010 May 1;86(2):211–218.

[124] Metabolic, Endocrine, and Genitourinary Pathobiology. DNA Methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am J Pathol. 2015;185(3):870–882. http://www.science direct.com/science/article/pii/S0002944014006907

[125] Ghaznavi H, Mahmoodi K, Soltanpour MS. A preliminary study of the association between the ABCA1 gene promoter DNA methylation and coronary artery disease risk. Mol Biol Res Commun. 2018 Jun;7(2):59–65.

[126] Guay S-P, Légard C, Houde -A-A, et al. Acetylsalicylic acid, aging and coronary artery disease are associated with ABCA1 DNA methylation in men. Clin Epigenetics. 2014 Jul 29;6(1):14.

[127] Zhou J, Chen L, Yang X, et al. Preliminary study of the relationship between promoter methylation of the ANGPTL2 gene and coronary heart disease. J Clin Lab Anal. 2018;21:22702.

[128] Nguyen A, Mamarbachi M, Turcot V, et al. Lower methylation of the ANGPTL2 gene in leukocytes from post-acute coronary syndrome patients. PLoS One. 2016 Apr 21;11(4):e0153920.

[129] Yamada Y, Horibe H, Oguri M, et al. Identification of novel hyper- or hypomethylated CpG sites and genes associated with atherosclerotic plaque using an epigenome-wide association study. Int J Mol Med. 2018 Feb 2;41(5):2724–2732.

[130] Chen X, Jiang D, Xu L, et al. Elevated methylation of cyclin dependent kinase inhibitor 2B contributes to the risk of coronary heart disease in women. Exp Ther Med. 2018 Nov 2;17(1):205–213.

[131] Zhong J, Chen X, Wu N, et al. Catechol-O-methyltransferase promoter hypomethylation is associated with the risk of coronary heart disease. Exp Ther Med. 2016 Nov 1;12(5):3445–3449.

[132] Miao L, Yin R-X, Zhang Q-H, et al. Integrated DNA methylation and gene expression analysis in the pathogenesis of coronary artery disease. Aging (Albany NY). 2019 Mar 7;11(5):1486–1500.

[133] Niu -P-P, Cao Y, Gong T, et al. Hypermethylation of DDAH2 promoter contributes to the dysfunction of endothelial progenitor cells in coronary artery disease patients. J Transl Med. 2014 Jun 16;12 (1):170.

[134] Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system [Internet]. Cardiovasc Res Narnia. 1999 Sep;1(4):985–91.

[135] Min J, Weitian Z, Peng C, et al. Correlation between insulin-induced estrogen receptor methylation and atherosclerosis. Cardiovasc Diabetol. 2016 Dec 10;15(1):156.

[136] Breitling LP, Salzmann K, Rothenbacher D, et al. F2RL3 methylation, and prognosis in stable coronary heart disease. Eur Heart J. 2012 Nov 1;33 (22):2841–2848.

[137] Guay S-P, Brisson D, Munger J, et al. ABCA1 gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia. Epigenetics. 2012 May 27;7 (5):464–472.

[138] Jia L, Zhu L, Wang JZ, et al. Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease. Atherosclerosis. 2013 Jun 1;228 (2):346–352.

[139] C-X L, Xu R-D, Cao M, et al. FOXP3 demethylation as a means of identifying quantitative defects in regulatory T cells in acute coronary syndrome. Atherosclerosis. 2013 Jul 1;229(1):263–270.

[140] Xu LL, Zheng D, Wang L, et al. GCK gene-body hypomethylation is associated with the risk of coronary heart disease. Biomed Res Int. 2014 Feb 17;2014:151723.

[141] Fan R WANGW-J, Q-L ZHONG, S-W DUAN, et al. Aberrant methylation of the GCK gene body is associated with the risk of essential hypertension. Mol Med Rep. 2015 Aug 1;12(2):2390–2394.

[142] Indumathi B, Katkam SK, Krishna LSR, et al. Dual effect of IL-6-174 G/C polymorphism and promoter methylation in the risk of coronary artery disease among south indians. Indian J Clin Biochem. 2019 Apr 21;34(2):180–187.

[143] Bakshe K, Vijayavargiya R, Aberrant DV. DNA methylation of M1-macrophage genes in coronary artery disease. Sci Rep. 2019 Dec 5;9(1):1429.

[144] Ghose S, Ghosh S, Tanwar VS, et al. Investigating Coronary Artery Disease methylome through targeted bisulfite sequencing. Gene. 2019 Dec 30;721:144107.

[145] Afzali M, Nakhaei A, Tabatabei SP, et al. Aberrant promoter methylation profile of Niemann-pick type C1 gene in cardiovascular disease. Iran Biomed J. 2013;17(2):77–83.

[146] Jiang D, Zheng D, Wang L, et al. Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. Ouedjans C, editor. PLoS One. 2013 Mar 28;8(3:e59752.

[147] Wei L, Zhao S, Wang G, et al. SMAD7 methylation as a novel marker in atherosclerosis. Biochem Biophys Res Commun. 2018 Feb 5;496(2):700–705.

[148] S-C MA, H-P ZHANG, F-Q KONG, et al. Integration of gene expression and DNA methylation profiles provides a molecular subtype for risk assessment in
atherosclerosis. Mol Med Rep. 2016 Jun 1;13 (6):4791–4799.

[149] Nakatoci M, Ichihara S, Yamamoto K, et al. Epigenome-wide association of myocardial infarction with DNA methylation sites at loci related to cardiovascular disease.

[150] Guay S-P, Légaré C, Brisson D, et al. Epigenetic and genetic variations at the TNNT1 gene locus are associated with HDL-C levels and coronary artery disease. Epigenomics. 2016 Mar 7;8(3):359–371.

[151] Huang Y-S, Zhi Y-F, Wang S-R. Hypermethylation of estrogen receptor-α gene in atheromatosis patients and its correlation with homocysteine. Pathophysiology. 2009 Oct 1;16(4):259–265.

[152] Akin-yemiju T, Do AN, Patki A, et al. Epigenome-wide association study of metabolic syndrome in African-American adults. Clin Epigenetics. 2018 Dec 10;10(1):49.

[153] ÅK H, Mendelson MM, Marioni RE, et al. Epigenetic patterns in blood associated with lipid traits predict incident coronary heart disease events and are enriched for results from genome-wide association studies. Circ Cardiovasc Genet. 2017 Jan;10(1):e001487.

[154] Peng P, Wang L, Yang X, et al. A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCGR genes and coronary heart disease. Coleman WB, editor. PLoS One. 2014 Aug 1;9(8):e102265.

[155] Pfeiffer L, Wahl S, Pilling LC, et al. DNA methylation of lipid-related genes affects blood lipid levels. Circ Cardiovasc Genet. 2015 Apr;8(2):334–342.

[156] Ištás G, Declerck K, Pudenz M, et al. Identification of differentially methylated BRCA1 and CRISP2 DNA regions as blood surrogate markers for cardiovascular disease. Sci Rep. 2017 Dec 11;7(1):1–14.

[157] Wang P, Shen C, Diao L, et al. Aberrant hypermethylation of aldehyde dehydrogenase 2 promoter upstream sequence in rats with experimental myocardial infarction. Biomed Res Int. 2015 Jan 5;2015:1–13.

[158] Glier MB, Green TJ, Devlin AM. Methyl nutrients, DNA methylation, and cardiovascular disease. Mol Nutr Food Res. 2014 Jan;58(1):172–182.

[159] Jiang D, Sun M, You L, et al. DNA methylation and hydroxymethylation are associated with the degree of coronary atherosclerosis in elderly patients with coronary heart disease. Life Sci. 2019 May 1;224:241–248.

[160] Kim M, Long TI, Arakawa K, et al. Methylation as a biomarker for cardiovascular disease risk. Bader JS, editor. PLoS One. 2010 Mar 15;5(3):e9692.

[161] Fernández-Sañés A, Sayols-Baxeras S, Subirana I, et al. Association between DNA methylation and coronary heart disease or other atherosclerotic events: a systematic review. Atherosclerosis. 2017 Aug 1;263:325–333.

[162] Aavik E, Babu M, Ylä-Herttuala S. DNA methylation processes in atherosclerotic plaque. Atherosclerosis. 2019 Feb 1;281:168–179.

[163] Hai Z, Zuo W. Aberrant DNA methylation in the pathogenesis of atherosclerosis. Clin Chim Acta. 2016 May 1;456:69–74.

[164] Turunen MP, Aavik E, Ylä-Herttuala S. Epigenetics and atherosclerosis. Biochim Biophys Acta Gen Subj. 2009 Sep 1;1790(9):886–891.

[165] Hiltunen MO, Turunen MP, Häkkinen TP, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002 Feb 3;7(1):5–11.

[166] Aavik E, Lumiäväärä H, Leppanen O, et al. Global DNA methylation analysis of human atherosclerotic plaques reveals extensive genomic hypomethylation and reactivation at imprinted locus 14q32 involving induction of a miRNA cluster. Eur Heart J. 2015 Apr 2;36 (16):993–1000.

[167] Pogribny IP, Beland FA. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci. 2009 Jul 27;66(14):2249–2261.

[168] Zaina SA, Garay-Sevilla ME, Hernández-González MA, et al. Extensive demethylation of normally hypermethylated CpG islands occurs in human atherosclerotic arteries. Int J Mol Med. 2010 Sep 21;26(5):691–700.

[169] Jiang Y, Zhang H, Sun T, et al. The comprehensive effects of hyperlipidemia and hyperhomocysteinemia on pathogenesis of atherosclerosis and DNA hypomethylation in Apo E-/ mice. Acta Biochim Biophys Sin (Shanghai). 2012 Oct 1;44(10):866–875.

[170] Zaina S, Heyn H, Carmona FJ, et al. DNA methylation map of human atherosclerosis. Circ Cardiovasc Genet. 2014 Oct 1;7(5):692–700.

[171] Lund G, Andersson L, Lauria M, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem. 2004 Jul 9;279(28):29147–29154.

[172] Wagner JR, Busche S, Ge B, et al. The relationship between DNA methylation, genetic and expression inter-individual variation in untransformed human fibroblasts. Genome Biol. 2014 Feb 20;15(2):R37.

[173] Maeder ML, Angstman JF, Richardson ME, et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol. 2013 Dec;31 (12):1137–1142.

[174] Lea AJ, Vockley CM, Johnston RA, et al. Genome-wide quantification of the effects of DNA methylation on human gene regulation. Elife. 2018;1:7.

[175] Anastasiadi D, Esteve-Codina A, Pfeffer F. Consistent inverse correlation between DNA methylation of the first intron and gene expression across tissues and species. Epigenet Chromat. 2018 Jun 29;11(1):37.

[176] Dunn J, Qiu H, Kim S, et al. Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis. The Journal
of Clinical Investigation. 2014 Jul 1;124(7):3187–3199.

[177] Cao Q, Wang X, Jia L, et al. Inhibiting DNA methylation by 5-Aza-2\'-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation. Endocrinology. 2014 Dec 1;155(12):4925–4938.

[178] Calkin AC, Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(8):1513–1518.

[179] Gribić E, Peterlin A, Kunej T, et al. PPARγ gene and atherosclerosis: genetic polymorphisms, epigenetics and therapeutic implications. Balk J Med Genet. 2018;21(1):39–46.

[180] Yu J, Qiu Y, Yang J, et al. DNMT1-PPARγ pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice. Sci Rep. 2016;17:6.

[181] Chistiakov DA, Orekhov AN, Bobryshev YV. Treatment of cardiovascular pathology with epigenetically active agents: focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation. Int J Cardiol. 2017;227:66–82.

[182] Nicorescu I, Dallinga GM, de Winther MPJ, et al. Potential epigenetic therapies for atherosclerosis treatment. Atherosclerosis. 2019;281:189–197.

[183] Schiano C, Vietri MT, Grimaldi V, et al. Epigenetic-related therapeutic challenges in cardiovascular disease. Trends Pharmacol Sci. 2015 Apr 1;36(4):226–235.

[184] Thomas PD, Campbell MJ, Kejariwal A, et al. PANTHER: A library of protein families and subfamilies indexed by function. Genome Res. 2003 Sep 1;13(9):2129–2141.

[185] Mi H, Muruganujan A, Huang X, et al. Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v14.0). Nat Protoc. 2019 Mar 1;14(3):703–721.

[186] Segiet OA, Piecuch A, L M, et al. Role of interleukins in heart failure with reduced ejection fraction. Anatol J Cardiol. 2019;22(6):287–299.

[187] Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020 Apr;24(9):1260–1280.

[188] Rose NR. Critical cytokine pathways to cardiac inflammation. J Interferon Cytokine Res. 2011;31(10):705–710.

[189] Aoyagi T, Matsu T. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des. 2011 Jul 11;17(18):1818–1824.

[190] Kitamura Y, Koide M, Akakabe Y, et al. Manipulation of cardiac phosphatidylinositol 3-kinase (PI3K)/Akt signaling by apoptosis regulator through modulating IAP expression (ARIA) regulates cardiomyocyte death during doxorubicin-induced cardiomyopathy. J Biol Chem. 2014 Jan 31;289(5):2788–2800.

[191] Hoyer FF, Nahrendorf M. Interferon-γ regulates cardiac myeloid cells in myocardial infarction. Cardiovasc Res. 2019;115:1815–1816.

[192] Ferreira LRP. Interferon-γ and other inflammatory mediators in cardiomyocyte signaling during Chagas disease cardiomyopathy. World J Cardiol. 2014;6(8):782.

[193] Wagner MA, Siddiqui MAQ, The JAK. STAT pathway in hypertrophic stress signaling and genomic stress response. JAK-STAT. 2012 Apr;1(2):131–141.

[194] Barry SP, Townsend PA, Latchman DS, et al. Role of the JAK–STAT pathway in myocardial injury. Trends Mol Med. 2007 Feb 1;13(2):82–89.

[195] Goswami R. JAK-STAT Signaling in Diseases. 1st ed. Boca Raton: CRC Press; 2020.

[196] Ivashkiv LB. Crosstalk with the Jak-STAT pathway in inflammation. In: Jak-Stat signaling: from basics to disease. Springer-Verlag Wien; 2012. p. 353–70.

[197] Boshuizen MCS, de Winther MPJ. Interferons as essential modulators of atherosclerosis. Arterioscler Thromb Vasc Biol. 2015 Jul 27;35(7):1579–1588.

[198] Zhang J, Alcaide P, Liu L, et al. Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS One. 2011;6:1.

[199] Whitman SC, Ravisankar P, Elam H, et al. Exogenous interferon-γ enhances atherosclerosis in apolipoprotein E−/− mice. Am J Pathol. 2000;157(6):1819–1824.

[200] Fougerat A, Gayral S, Malet N, et al. Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?. Clinical Science. 2009;116:791–804.

[201] Ghigo A, Li M. Phosphoinositide 3-kinase: friend and foe in cardiovascular disease. Front Pharmacol. 2015 Aug 13;6(Aug):169.

[202] Choi KH, Kim JE, Song NR, et al. Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res. 2010 Mar 1;85(4):836–844.

[203] Buckely ML, Williams JO, Chan Y-H, et al. The interleukin-33-mediated inhibition of expression of two key genes implicated in atherosclerosis in human macrophages requires MAP kinase, phosphoinositide 3-kinase and nuclear factor-xB signaling pathways. Sci Rep. 2019;9(1):11317.

[204] Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol. 2017;70(18):2278–2289.

[205] Hartman J, Frishman WH. Inflammation and atherosclerosis: A review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiology in Review. 2014;22:147–151.

[206] Tian Y, Ling X, Chen D, et al. Interleukin-36 receptor antagonist attenuates atherosclerosis development by inhibiting NLRP3 inflammasome. J Cell Physiol. 2020 Dec 2;235(12):9992–9996.
[207] Fatkhullina AR, Peshkova IO, Koltsova EK. The role of cytokines in the development of atherosclerosis. Biochemistry (Moscow). 2016;81:1358–1370.

[208] Von der Thüsen JH, Kuiper J, Van Berkel TJC, et al. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev. 2003;55:133–166.

[209] Wouters K, Deleye Y, Hannou SA, et al. The tumour suppressor CDKN2A/p16INK4a regulates adipogenesis and bone marrow-dependent development of perivascular adipose tissue. Diab Vasc Dis Res. 2017 Nov 1;14 (6):516–524.

[210] Musa A, Shabeeb D. Radiation-induced heart diseases: protective effects of natural products. Med (B Aires). 2019 May 9;55(5):126.

[211] Kolivand S, Amini P, Saffar H, et al. Selenium-L-methionine modulates radiation injury and Duox1 and Duox2 upregulation in rat’s heart tissues. J Cardiovasc Thorac Res. 2019 Jun 27;11 (2):121–126.

[212] Siddique AN, Nunna S, Rajavelu A, et al. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J Mol Biol. 2013 Feb 8;425(3):479–491.

[213] Xu X, Tao Y, Gao X, et al. A CRISPR-based approach for targeted DNA demethylation. Cell Discov. 2016 May 3;2(1):1–12.

[214] Hanzawa N, Hashimoto K, Yuan X, et al. Targeted DNA demethylation of the Fgf21 promoter by CRISPR/dCas9-mediated epigenome editing. Sci Rep. 2020 Dec 1;10(1):1–14.

[215] Tang C, Oram JF. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim Biophys Acta - Mol Cell Biol Lipids. 2009 Jul 1;1791(7):563–572.

[216] Rudel LL, Lee RG, Cockman TL. Acyl coenzyme a: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr Opin Lipidol. 2001 Apr;12(2):121–127.

[217] Chen C-H, Budas GR, Churchill EN, et al. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science. 2008 Sep 12;321 (5895):1493–1495.

[218] Gong D, Zhang H, Hu S. Mitochondrial aldehyde dehydrogenase 2 activation and cardioprotection. J Mol Cell Cardiol. 2013 Feb 1;55:58–63.

[219] Yang M-Y, Wang Y-B, Han B, et al. Activation of aldehyde dehydrogenase 2 slows down the progression of atherosclerosis via attenuation of ER stress and apoptosis in smooth muscle cells. Acta Pharmacol Sin. 2018 Jan;39(1):48–58.

[220] Kadomatsu T, Endo M, Miyata K, et al. Diverse roles of ANGPTL2 in physiology and pathophysiology. Trends Endocrinol Metab. 2014 May 1;25(5):245–254.

[221] van Westerop LLM, Arts-de Jong M, Hoogerbrugge N, et al. Cardiovascular risk of BRCA1/2 mutation carriers: a review. Maturitas. 2016 Sep 1;91:135–139. DOI:10.1016/j.maturitas.2016.06.012.

[222] Chen M, Ni J, Zhang Y, et al. ERAP75 functions as a coactivator to enhance estrogen receptor a transactivation in prostate stromal cells. Prostate. 2008 Sep 1;68 (12):1273–1282.

[223] Papait R, Kunderfranco P, Stirparo GG, et al. Long noncoding RNA: a new player of heart failure? J Cardiovasc Transl Res. 2013 Dec 9;6(6):876–883.

[224] Bastos P, Gomes T, Ribeiro L. Catechol-O-methyltransferase (COMT): an update on Its Role in Cancer, Neurological and Cardiovascular Diseases. Rev Physiol Biochem Pharmacol. 2017;173:1–39.

[225] Akhtar S, Grems F, Kiessling F, et al. CXCL12 promotes the stabilization of atherosclerotic lesions mediated by smooth muscle progenitor cells in Apoe-deficient mice. Arterioscler Thromb Vasc Biol. 2013 Apr;33(4):679–686.

[226] Farouk SS, Rader DJ, Reilly MP, et al. CXCL12: a new player in coronary disease identified through human genetics. Trends Cardiovasc Med. 2010 Aug;20 (6):204–209. DOI:10.1016/j.tcm.2011.08.002.

[227] van der Vorst EPC, Döring Y, Weber C. Chemokines and their receptors in Atherosclerosis. J Mol Med. 2015 Sep 15;93(9):963–971.

[228] Zhang J, Liu J, Li Z, et al. Dysfunction of endothelial NO system originated from homocysteine-induced aberrant methylation pattern in promoter region of DDAH2 gene. Chin Med J (Engl). 2007 Dec 5;120 (23):2132–2137.

[229] Menazza S, Murphy E. The expanding complexity of estrogen receptor signaling in the cardiovascular system. Circ Res. 2016 Mar 18;118(6):994–1007.

[230] Mahmoodzadeh S, Eder S, Nordmeyer J, et al. Estrogen receptor alpha up-regulation and redistribution in human heart failure. Faseb J. 2006 May 1;20 (7):926–934.

[231] Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006 Mar 1;116 (3):561–570.

[232] Rothenbacher D, Koenig W, Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med. 2006 Dec 11;166(22):2455.

[233] Zhang Y, Yang R, Burwinkel B, et al. 3-methylation as a biomarker of current and lifetime smoking exposures. Environ Health Perspect. 2014 Feb;122 (2):131–137.

[234] Waters CE, Saldivar JC, Hosseini SA, et al. FHIT gene product: tumor suppressor and genome &quot;caretaker&quot;. Cell Mol Life Sci. 2014 Dec;71(23):4577–4587.

[235] Di Paola R, Marucci A, Trischitta V. GALNT2 effect on HDL-cholesterol and triglycerides levels in
humans: evidence of pleiotropy?. Nutr Metab Cardiovasc Dis. 2017 Apr 1;27(4):281–282.

[236] Marucci A, Antonucci A, De Bonis C, et al. GALNT2 as a novel modulator of adipogenesis and adipocyte insulin signaling. Int J Obes. 2019 Apr;30.

[237] Webster RJ, Harrington NM, Weedon MN, et al. The association of common genetic variants in the APOA5, LPL and GCK genes with longitudinal changes in metabolic and cardiovascular traits. Diabetologia. 2009 Jan 19;52(1):106–114.

[238] Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci. 2009 Jan 26;66(1):27–42.

[239] Tracy MR, Dormans JP, Kusumi K. Klippel-Feil syndrome. Clin Orthop Relat Res. 2004 Jul;424:183–190.

[240] YAMADA Y, NISHIDA T, HORIBE H, et al. Identification of hypothalamic and hypermetabolic genes related to atherosclerosis by a genome-wide analysis of DNA methylation. Int J Mol Med. 2014 May 1;33 (5):1355–1363.

[241] Nova-Lampeti E, Aguilera V, Oporto K, et al. Hox genes in adult tissues and their role in endothelial cell differentiation and angiogenesis. In: Endothelial dysfunction - old concepts and new challenges. InTech; 2018.

[242] Gorski DH, Patel CV, Walsh K. Homeobox transcription factor regulation in the cardiovascular system. Trends Cardiovasc Med. 1993 Sep 1;3 (5):184–190.

[243] Fontes JA, Rose NR, Chiháková D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015 Jul;74(1):62.

[244] van der Heijden T, Bot I, The KJ. IL-12 cytokine family in cardiovascular diseases. Cytokine. 2019 Oct 1;122:154188. DOI:10.1016/j.cyto.2017.10.010.

[245] Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan 19;333 (1–2):191–201.

[246] Shah A. Inducible nitric oxide synthase and cardiovascular disease. Cardiovasc Res. 2000 Jan 1;45(1):148–155.

[247] Davies RW, Wells GA, Stewart AFR, et al. A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet. 2012 Apr 1;5(2):217–225.

[248] Missala I, Kassner U, Steinhagen-Thiessen E, et al. Review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis. Int J Rheumatol. 2012 Dec 5;2012:480784.

[249] Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009 Dec 24;361 (26):2518–2528.

[250] Rozanski A, Takano APC, Kato PN, et al. M-protein is down-regulated in cardiac hypertrophy driven by thyroid hormone in rats. Mol Endocrinol. 2013 Dec;27(12):2055–2065.

[251] Sequeira V, Nijenkamp LL, Regan JA, van der Velden J. The physiological role of cardiac cytoskeleton and its alterations in heart failure. Biochim Biophys Acta - Biomembr. 2014 Feb 1;1838(2):700–722.

[252] Liu X, Xu H, Xu H, et al. New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin. bioRxiv. 2018:9:411165.

[253] Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012 Apr 1;33 (7):829–837.

[254] Yu X-H, Jiang N, Yao P-B, et al. NPC1, intracellular cholesterol trafficking and atherosclerosis. Clin Chim Acta. 2014 Feb 15;429:69–75.

[255] Sutton BS, Crosslin DR, Shah SH, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case–control and family datasets. Hum Mol Genet. 2008 May 1;17(9):1318–1328.

[256] Karabina S, Ninio E. Plasma PAF Ah/PLA2G7 genetic variability, cardiovascular disease, and clinical trials. Enzymes. 2015;38:145–155.

[257] Sorrentino S. The eight human “canonical” ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins. FEBS Lett. 2010 Jun 3;584(11):2194–2200.

[258] Koczera P, Martin L, Marx G, et al. The ribonuclease a superfamily in humans: canonical RNases as the buttress of innate immunity. Int J Mol Sci. 2016 Aug 5;17(8):1278.

[259] Wei L, Chao N, Gao S, et al. Homocysteine induces vascular inflammatory response via SMAD7 hypermethylation in human umbilical vein smooth muscle cells. Microvasc Res. 2018 Nov 1;120:8–12.

[260] Papait R, Greco C, Kunderfranco P, et al. Epigenetics: a new mechanism of regulation of heart failure?. Basic Res Cardiol. 2013 Jul 6;108(4):361.

[261] Guo X, Wang X, Wang Y, et al. Variants in the SMARCA4 gene was associated with coronary heart disease susceptibility in Chinese han population. Oncotarget. 2017 Jan 31;8(5):7350.

[262] Chmielewski S, Piaszyk-Borychowska A, Wesoly J, et al. STAT1 and IRF8 in vascular inflammation and cardiovascular disease: diagnostic and therapeutic potential. Int Rev Immunol. 2016 Sep 2;35 (5):434–454.

[263] Hammer S, Toenjes M, Lange M, et al. Characterization of TBX20 in human hearts and its regulation by TFAP2. J Cell Biochem. 2008 Jun 1;104 (3):1022–1033.

[264] Shen T, Zhu Y, Patel J, et al. T-Box20 suppresses oxidized low-density lipoprotein-induced human vascular endothelial cell injury by upregulation of PPARY. Cell Physiol Biochem. 2013;32 (5):1137–1150.
[265] Johnson JL. Metalloproteinases in atherosclerosis. Eur J Pharmacol. 2017 Dec 5;816:93–106.

[266] Guay S-P, Voisin G, Brisson D, et al. Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration. Epigenomics. 2012 Dec;4(6):623–639.

[267] Li C, Wang F, Yang Y, et al. Significant association of SNP rs2106261 in the ZFHX3 gene with atrial fibrillation in a Chinese Han GeneID population. Hum Genet. 2011 Mar;129(3):239–246. DOI:10.1007/s00439-010-0912-6.

[268] Kao Y-H, Hsu J-C, Chen Y-C, et al. ZFHX3 knockdown increases arrhythmogenesis and dysregulates calcium homeostasis in HL-1 atrial myocytes. Int J Cardiol. 2016 May 1;210:85–92.

[269] Xue Y, Shi N, Zhang B, et al. Genetic variant in ZFHX3 gene on 16q22 associated with risk of stroke in Chinese Han population. Int J Clin Exp Pathol. 2016;9:8650–8656.

[270] Liu C, Yao M-D, Li C-P, et al. Silencing of circular RNA-ZNF609 ameliorates vascular endothelial dysfunction. Theranostics. 2017;7(11):2863–2877. DOI:10.7150/thno.19353.

[271] Lin T, Zhang X, Lu Y, et al. Identification of circular RNA related to inflammation-induced lymphangiogenesis by microarray analysis. DNA Cell Biol. 2019 Aug;38(8):887–894.